Seven Eight Capital, LP Ionis Pharmaceuticals Inc Transaction History

Seven Eight Capital, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$40.06 - $51.86 $696,803 - $902,052	17,394 New	17,394 $696,000
Q2 2023 Aug 14, 2023	BUY	$34.73 - $43.33 $214,561 - $267,692	6,178 New	6,178 $253,000
Q4 2022 Feb 13, 2023	BUY	$37.12 - $46.52 $25,984 - $32,564	700 Added 13.23%	5,990 $226,000
Q3 2022 Nov 10, 2022	SELL	$36.54 - $48.66 $6,102 - $8,126	-167 Reduced 3.06%	5,290 $234,000
Q2 2022 Aug 04, 2022	SELL	$31.71 - $43.0 $327,849 - $444,577	-10,339 Reduced 65.45%	5,457 $202,000
Q1 2022 May 11, 2022	BUY	$29.88 - $37.04 $471,984 - $585,083	15,796 New	15,796 $585,000
Q4 2020 Feb 09, 2021	SELL	$45.3 - $60.27 $978,479 - $1.3 Million	-21,600 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$47.45 - $62.95 $1.02 Million - $1.36 Million	21,600 New	21,600 $1.03 Million
Q2 2019 Aug 12, 2019	SELL	$62.09 - $86.14 $724,590 - $1.01 Million	-11,670 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$52.92 - $81.17 $617,576 - $947,253	11,670 New	11,670 $947,000

416

140M

861K

714K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $4.41B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.